The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) [11], demonstrated lower rates of the composite 3-point major cardiovascular event (MACE) outcome of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (14% relative risk reduction); death from CV causes (38% relative risk reduction); death from any cause (32% relative risk reduction); and hospitalization for heart failure (35% relative risk reduction), with the SGLT2 inhibitor empagliflozin compared with placebo, when added to standard care [11]. Here, SLC5A2 is linked to heart failure.